Simultaneous quantification and semi-quantification of ginkgolic acids and their metabolites in rat plasma by UHPLC–LTQ–Orbitrap–MS and its application to pharmacokinetics study

Add time:08/29/2019    Source:sciencedirect.com

A highly sensitive method using ultra-high-pressure liquid chromatography coupled with linear ion trap-Orbitrap tandem mass spectrometry (UHPLC–LTQ–Orbitrap–MS) has been developed and validated for the simultaneous identification and quantification of ginkgolic acids and semi-quantification of their metabolites in rat plasma. For the five selected ginkgolic acids, the method was found to be with good linearities (r > 0.9991), good intra- and inter-day precisions (RSD < 15%), and good accuracies (RE, from −10.33% to 4.92%) as well. Extraction recoveries, matrix effects and stabilities for rat plasm samples were within the required limits. The validated method was successfully applied to investigate the pharmacokinetics of the five ginkgolic acids in rat plasma after oral administration of 3 dosage groups (900 mg/kg, 300 mg/kg and 100 mg/kg). Meanwhile, six metabolites of GA (15:1) and GA (17:1) were identified by comparison of MS data with reported values. The results of validation in terms of linear ranges, precisions and stabilities were established for semi-quantification of metabolites. The curves of relative changes of these metabolites during the metabolic process were constructed by plotting the peak area ratios of metabolites to salicylic acid (internal standard, IS), respectively. Double peaks were observed in all 3 dose groups. Different type of metabolites and different dosage of each metabolite both resulted in different Tmax.

We also recommend Trading Suppliers and Manufacturers of Ginkgolic Acid C17:1 (cas 111047-30-4). Pls Click Website Link as below: cas 111047-30-4 suppliers

Prev:Ginkgolic acids and Ginkgo biloba extract inhibit Escherichia coli O157:H7 and Staphylococcus aureus biofilm formation
Next:Research paperCyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP)